Compare Medpace Holdings Inc (MEDP) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Rivian Automotive, Inc. — how do they compare? Medpace Holdings Inc trades at $536.41 (market cap $15.35B), while Rivian Automotive, Inc. trades at $17.64 (market cap $25.26B). The key difference: Rivian Automotive, Inc. is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| MEDP | RIVN | |
|---|---|---|
Market Cap | $15.35B | $25.26B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $22.45 |
52-Week Low | $308.88 | $11.64 |
Enterprise Value | $14.82B | $27.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $534.49, down 0.6% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.83. Recent quarters have consistently beaten EPS estimates, and 2026 forecasts project revenue growth to $2.7B. News highlights focus on CRO demand shifts and a class action lawsuit filed in June 2026.
Outlook remains positive given earnings momentum and sector demand, but risks include legal overhangs and high valuation multiples. Analyst consensus is mixed with a $497 price target below current levels, suggesting cautious optimism amid near-term headwinds.
Rivian Automotive (RIVN) trades at $17.60, up 0.83% with a bullish technical signal from moving averages. The company shows improving financial trends with revenue growth to $5.39B in 2025 and narrowing losses, though it remains unprofitable with a -63.62% net margin. Recent news highlights focus on the R2 vehicle launch and California's EV incentives, while analyst consensus is a Buy with a $19.22 price target.
The outlook hinges on Rivian's path to profitability and R2 execution, offering upside if production scales successfully. Key risks include cash burn, competitive EV market pressures, and reliance on capital raises, requiring careful monitoring of quarterly earnings and guidance updates for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
